{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2004"],"condition":["Metastatic Colorectal Cancer","Colorectal cancer","Colorectal Neoplasms"],"disease":["Metastatic Colorectal Cancer","Colorectal Cancer","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2023552"],"study_start_month":["9"],"keyword":["Irinotecan","Oxaliplatin","Capecitabine","Cetuximab"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer.","description":"A randomized phase II-study to evaluate the safety and efficacy of capecitabine plus irinotecan plus cetuximab compared to capecitabine plus oxaliplatin plus cetuximab in first-line treatment of patients with metastatic colorectal cancer.","dates":{"creation":"2004-09-15"},"accession":"2023552","cross_references":{"ClinicalTrials___gov":["NCT00254137"]}}